FDA Approved: MATZIM LA — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

FDA approved a supplemental application for MATZIM LA (diltiazem hydrochloride) from Actavis Pharma, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Atrial Fibrillation
• Atrial Flutter
• Hypertension
• Paroxysmal Supraventricular Tachycardia

Drugs mentioned

• MATZIM LA (DILTIAZEM HYDROCHLORIDE)

Snippet

SUPPL AP for MATZIM LA (DILTIAZEM HYDROCHLORIDE)